Stockscreener 앱 받기
0.00
100.00%
-10.30
전일 마감가:
$10.30
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$10.72
Apogee Acquisition Corp Stock (AACPU) Company Profile
명칭
Apogee Acquisition Corp
전화
771.210.4643
주소
2106 HOUSE AVE SUITE 375, CHEYENNE
Compare AACPU vs LION, XXI, UMAC, CCXI, DMII
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AACPU
Apogee Acquisition Corp
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
LION
Lionsgate Studios Corp
|
11.44 | 3.35B | 2.63B | -175.60M | 11.40M | -0.7173 |
XXI
Twenty One Capital Inc
|
6.61 | 1.89B | 0 | 4.35M | 456.40K | 0.3397 |
UMAC
Unusual Machines Inc
|
23.51 | 1.15B | 17.25M | -5.64M | -40.16M | -0.3337 |
CCXI
Churchill Capital Corp Xi
|
13.17 | 686.22M | 0 | 0 | 0 | 0.0647 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.15 | 647.37M | 0 | 8.58M | -1.11M | 0.134 |
Apogee Acquisition Corp 주식(AACPU)의 최신 뉴스
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
AbbVie-owned Apogee Therapeutics (APGE) pulls unsold stock - Stock Titan
Apogee Therapeutics (APGE) director-linked funds fully exit in AbbVie deal - Stock Titan
Apogee Therapeutics (APGE) CMO cashes out stock and options in AbbVie deal - Stock Titan
Director cashes out Apogee (NASDAQ: APGE) stake in AbbVie merger - Stock Titan
Apogee merger pays $135.11 per share in cash | APGE SEC FilingForm SCHEDULE 13D/A - Stock Titan
AbbVie Finalizes $10.9 Billion Acquisition of Apogee Therapeutics, Initiates Nasdaq Delisting - Kalkine Media
AbbVie Completes Acquisition of Apogee Therapeutics - Investing News Network
AbbVie Completes $10.9 Billion Acquisition of Apogee Therapeutics - Minichart
AbbVie Completes $10.9 Billion Apogee Acquisition, Reaffirms 2026 EPS Guidance - Minichart
AbbVie Closes Apogee Acquisition to Expand Immunology Portfolio - TipRanks
AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE) - seekingalpha.com
TOMI Regains Nasdaq Equity Compliance After $2.5M Debt Conversion - Minichart
Apogee Acquisition (AACP) Stock Chart and Price History 2026 - MarketBeat
ABBV climbs around 1.5% after double-digit revenue growth and Apogee acquisition - Traders Union
ARISTEIA CAPITAL, L.L.C. Initiates Position in Apogee Acquisitio - GuruFocus
Apogee Acquisition Corp Q2 2026: Net income $1.13M, EPS $0.08— 10-Q Summary - TradingView
Apogee Acquisition (AACP) faces 2027 deal-or-liquidation deadline - Stock Titan
Apogee Acquisition Corp Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AbbVie Raises $10 Billion in Debt to Fund Apogee Acquisition - Minichart
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
AbbVie (NYSE: ABBV) issues new senior notes with Apogee-linked redemption - Stock Titan
AbbVie Inc Stock (ABBV) Closed Up by 3.48% on Aug 18: Key Drivers Unveiled - TradingKey
Apogee Acquisition (AACP) Stock Trends and Sentiment 2026 - MarketBeat
Apogee Acquisition Corp SEC Filing (Aug 14, 2026) - Stock Titan
Polar Asset Management (AACP) discloses 7.2% stake in Apogee Acquisition Corp - Stock Titan
Highbridge Capital Management (AACP) discloses 9.2% ownership of Apogee Acquisition - Stock Titan
Apogee Acquisition Corp (AACP) investors report 0% ownership in 13G/A exit - Stock Titan
Apogee Acquisition Corp (AACP) investor reports 7.05% holding in Class A shares - Stock Titan
Glazer Capital (AACP) discloses 5.45% Apogee Acquisition Corp stake in 13G - Stock Titan
Magnetar entities disclose 1.25M AACP shares on 13G, holding 7.05% stake - Stock Titan
Apogee Therapeutics Shareholders Endorse AbbVie Acquisition in Special Meeting - Kalkine Media
AbbVie agrees $10.9bn Apogee Therapeutics deal - Financier Worldwide
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? - Yahoo Finance
Apogee Therapeutics Reports Q2 2026 Results and Announces Merger Agreement with AbbVie Subsidiary - Kalkine Media
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results - Quiver Quantitative
Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75 - Stock Titan
AbbVie (ABBV) Announces $10 Billion Multi-Tranche Senior Notes O - GuruFocus
AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition, Bloomberg Reports - marketscreener.com
AbbVie Announces Multi-Tranche Senior Note Offering to Finance Apogee Therapeutics Acquisition - Kalkine Media
Equity in earnings of Apogee Acquisition Corp – NASDAQ:AACPW - TradingView
Upcoming & Recent IPO'sIPOs Calendar - finance.yahoo.com
Enterprise value to EBITDA forward of Apogee Acquisition Corp – NASDAQ:AACPR - TradingView
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps - WSJ
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc.APGE - Business Wire
AACP|Apogee Acquisition Ord Shs Class A|Price:9.997|Chg%:+0.007 - TradingKey
Apogee Acquisition Corp Revenue Breakdown – BOATS:AACPU - TradingView
Apogee Acquisition Corp Revenue Breakdown – NASDAQ:AACPR - TradingView
Apogee Acquisition Corp Revenue Breakdown – BOATS:AACPR - TradingView
Apogee Acquisition Corp Revenue Breakdown – NASDAQ:AACP - TradingView
Apogee Acquisition Corp (AACPU) 재무 분석
Apogee Acquisition Corp (AACPU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.25%
자본화:
|
볼륨(24시간):